Syngene International not only reported a steady set of numbers but also guided for a healthy underlying growth outlook. While it continues to be in the investment phase, risks to watch are execution in the field of biologics and pending regulatory approvals. MC Pro suggests using market corrections to accumulate the stock for the long term. Here's why!